H
Hironori Ninomiya
Researcher at Japanese Foundation for Cancer Research
Publications - 88
Citations - 3586
Hironori Ninomiya is an academic researcher from Japanese Foundation for Cancer Research. The author has contributed to research in topics: Lung cancer & Adenocarcinoma. The author has an hindex of 20, co-authored 80 publications receiving 3083 citations. Previous affiliations of Hironori Ninomiya include Fukuoka University.
Papers
More filters
Journal ArticleDOI
RET, ROS1 and ALK fusions in lung cancer.
Kengo Takeuchi,Manabu Soda,Yuki Togashi,Ritsuro Suzuki,Seiji Sakata,Satoko Hatano,Reimi Asaka,Wakako Hamanaka,Hironori Ninomiya,Hirofumi Uehara,Young Lim Choi,Yukitoshi Satoh,Yukitoshi Satoh,Sakae Okumura,Ken Nakagawa,Hiroyuki Mano,Hiroyuki Mano,Yuichi Ishikawa +17 more
TL;DR: A multivariate analysis of 1,116 adenocarcinomas containing 71 kinase-fusion–positive adenokcinomas identified four independent factors that are indicators of poor prognosis: age ≥50 years, male sex, high pathological stage and negative kinase -fusion status.
Journal ArticleDOI
EML4-ALK Fusion Is Linked to Histological Characteristics in a Subset of Lung Cancers
Kentaro Inamura,Kengo Takeuchi,Yuki Togashi,Kimie Nomura,Hironori Ninomiya,Michiyo Okui,Yukitoshi Satoh,Sakae Okumura,Ken Nakagawa,Manabu Soda,Young Lim Choi,Toshiro Niki,Hiroyuki Mano,Yuichi Ishikawa +13 more
TL;DR: In the present first investigation of EML4-ALK fusion in a large study of lung cancers, an interesting histotype-genotype relationship is found and the fusion protein could be detected by immunohistochemistry, pointing to possible clinical applications.
Journal ArticleDOI
EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset.
Kentaro Inamura,Kengo Takeuchi,Yuki Togashi,Satoko Hatano,Hironori Ninomiya,Noriko Motoi,Mingyon Mun,Yukinori Sakao,Sakae Okumura,Ken Nakagawa,Manabu Soda,Young Lim Choi,Hiroyuki Mano,Yuichi Ishikawa +13 more
TL;DR: EML4-ALK-positive tumors may form a distinct entity among lung adenocarcinomas, characterized by young onset, acinar histology, no or rare mutations in EGFR, KRAS, and TP53, and a TTF-1 cell lineage, all in agreement with the prevalence in non- or light smokers.
Journal ArticleDOI
P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer.
Ryohei Katayama,Takuya Sakashita,Takuya Sakashita,Noriko Yanagitani,Hironori Ninomiya,Atsushi Horiike,Luc Friboulet,Justin F. Gainor,Noriko Motoi,Akito Dobashi,Seiji Sakata,Yuichi Tambo,Satoru Kitazono,Shigeo Sato,Sumie Koike,A. John Iafrate,Mari Mino-Kenudson,Yuichi Ishikawa,Alice T. Shaw,Jeffrey A. Engelman,Kengo Takeuchi,Makoto Nishio,Naoya Fujita +22 more
TL;DR: P-glycoprotein (P-gp/ABCB1) overexpression as a ceritinib resistance mechanism in ALK-rearranged NSCLC patients is reported and it is suggested that alectinib, PF-06463922, or P-gp inhibitor with cerit inib could overcome the ceritInib or crizotinib resistance mediated by P- gp overexpressive.
Journal ArticleDOI
EBUS-TBNA as a Promising Method for the Evaluation of Tumor PD-L1 Expression in Lung Cancer
Rie Sakakibara,Rie Sakakibara,Kentaro Inamura,Yuichi Tambo,Hironori Ninomiya,Satoru Kitazono,Noriko Yanagitani,Atsushi Horiike,Fumiyoshi Ohyanagi,Yosuke Matsuura,Masayuki Nakao,Mingyon Mun,Sakae Okumura,Naohiko Inase,Makoto Nishio,Noriko Motoi,Yuichi Ishikawa +16 more
TL;DR: EBUS-TBNA is suggested as a promising method to evaluate programmed death-ligand 1 (PD-L1) expression in lung cancer.